MindImmune Therapeutics Email Formats

Biotechnology Research • Kingston, Rhode Island, United States • 11-20 Employees

MindImmune Therapeutics Email Formats

MindImmune Therapeutics uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	42.1%
{first name}@company.com	john@company.com	25.3%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	14.8%
{first name}{last name}@company.com	johndoe@company.com	10.2%
{last name}@company.com	doe@company.com	7.6%

Key Contacts at MindImmune Therapeutics

Frank Menniti

Founder, Chief Science Officer

Bob Nelson

Co-Founder | Vice President Of Biology

Joseph Hedde

Research Director

Kenneth Rose

Director Of Translational Science

Company overview

Headquarters	130 Flagg Rd, Kingston, Rhode Island 02881, US
Phone number	+14012254612
Website	mindimmune.com
NAICS	541714
SIC	283
Keywords	Neuroscience, Pharmaceutical R&D, Neuroimmunology, Neuroinflammation
Founded	2016
Employees	11-20
Socials

About MindImmune Therapeutics

MindImmune is a pre-clinical stage company focused on neuro-inflammation, targeting Alzheimer's disease (AD) as initial clinical indication. The company's lead program is an antibody-based therapeutic, aiming to inhibit an innate immune response originating in the periphery which is triggered by AD pathology. The lead program is in late stage pre-clinical development, contemplating IND filing near-term. If successful in clinical development, the company's therapeutic strategy would represent a fundamental breakthrough for the AD field. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Director

Founder/Owner

Entry

Employees by Department

MindImmune Therapeutics has 5 employees across 4 departments.

Departments

Number of employees

Funding Data

Explore MindImmune Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2022-07-13	4	$12,400,000

Funding Insights

$12,400,000

Total funding amount

$12,400,000

Most recent funding amount

Number of funding rounds

MindImmune Therapeutics Tech Stack

Discover the technologies and tools that power MindImmune Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Google Workspace

jQuery

JavaScript libraries

Google Tag Manager

Tag managers

GoDaddy

Hosting

PHP

Programming languages

Open Graph

Miscellaneous

Flywheel

Hosting

WordPress

Blogs

core-js

JavaScript libraries

Divi

Page builders

jQuery Migrate

JavaScript libraries

Google Analytics

Analytics

Frequently asked questions

MindImmune Therapeutics is located in Kingston, Rhode Island, US.

You can reach MindImmune Therapeutics at +14012254612.

MindImmune Therapeutics was founded in 2016, making it 10 years old. The company has established itself as a significant player in its industry over this time.

MindImmune Therapeutics has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

MindImmune Therapeutics has raised a total of $12,400,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at MindImmune Therapeutics

Frank Menniti

Founder, Chief Science Officer

Bob Nelson

Co-Founder | Vice President Of Biology

Joseph Hedde

Research Director

Kenneth Rose

Director Of Translational Science

4.8

40,000 users